Steminent Biotherapeutics (ROCO:7729) EPS without NRI: NT$-2.91 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7729 Steminent Biotherapeutics Inc ROCO:7729
11 GF Score
Price NT$77.50
! 4 Warning Signs
View Full Analysis

What is Steminent Biotherapeutics EPS without NRI?

Steminent Biotherapeutics ROCO:7729 +0.78% 11 EPS without NRI is NT$-2.91 as of Dec. 2025. GuruFocus rates ROCO:7729 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 1,166 Biotechnology companies, Steminent Biotherapeutics ranks worse than 84.91% on this metric.

Steminent Biotherapeutics's earnings per share without non-recurring items for the six months ended in Dec. 2025 was NT$-1.59. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-2.91.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Steminent Biotherapeutics's EPS without NRI or its related term are showing as below:

ROCO:7729' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.2   Med: -18.1   Max: 4.7
Current: -18.1

ROCO:7729's 3-Year EPS without NRI Growth Rate is ranked worse than
84.91% of 1166 companies
in the Biotechnology industry
Industry Median: 16.4 vs ROCO:7729: -18.10

Steminent Biotherapeutics's EPS (Diluted) for the six months ended in Dec. 2025 was NT$-1.59. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-2.91.

Steminent Biotherapeutics's EPS (Basic) for the six months ended in Dec. 2025 was NT$-1.59. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-2.91.


Steminent Biotherapeutics  (ROCO:7729) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Steminent Biotherapeutics EPS without NRI Related Terms


Steminent Biotherapeutics EPS without NRI Historical Data

* Premium members only.

The historical data trend for Steminent Biotherapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steminent Biotherapeutics EPS without NRI Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial -3.23 -1.76 -2.45 -2.80 -2.91

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.59 -1.38 -1.42 -1.31 -1.59

ROCO:7729 vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Steminent Biotherapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steminent Biotherapeutics PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Steminent Biotherapeutics's PE Ratio without NRI falls into.


ROCO:7729
11GF Score
Steminent Biotherapeutics Inc ROCO:7729
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steminent Biotherapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of NT$-2.91 mean?
Steminent Biotherapeutics (ROCO:7729) has a EPS without NRI of NT$-2.91 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Steminent Biotherapeutics and its competitors. According to the industry distribution chart, Steminent Biotherapeutics ranks #990 out of 1166 companies in the Biotechnology industry, placing it in the top 84.9%.
Is Steminent Biotherapeutics' EPS without NRI too high?
Steminent Biotherapeutics' current EPS without NRI is NT$-2.91. Based on the distribution chart, Steminent Biotherapeutics ranks #990 out of 1166 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Steminent Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Steminent Biotherapeutics ranks #990 out of 1166 companies for EPS without NRI. This places Steminent Biotherapeutics in the lower half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Steminent Biotherapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steminent Biotherapeutics's current EPS without NRI is NT$-2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current EPS without NRI of NT$-2.91. The current EPS without NRI is NT$-2.91. Steminent Biotherapeutics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current EPS without NRI is NT$-2.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Steminent Biotherapeutics Business Description

Address No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
11GF Score

Get the complete analysis for ROCO:7729

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$77.50
Price